Spyre Therapeutics (SYRE) Liabilities and Shareholders Equity (2015 - 2026)

Spyre Therapeutics (SYRE) has 12 years of Liabilities and Shareholders Equity data on file, last reported at $764.0 million in Q1 2026.

• For the quarter ending Q1 2026, Liabilities and Shareholders Equity rose 34.08% year-over-year to $764.0 million; the trailing twelve-month figure through Mar 2026 stood at $2.6 billion (up 27.01% YoY), and the FY2025 full-year result was $777.8 million, up 27.82% from the prior year.
• Liabilities and Shareholders Equity for Q1 2026 stood at $764.0 million, down from $777.8 million in the prior quarter.
• Across five years, Liabilities and Shareholders Equity topped out at $777.8 million in Q4 2025 and bottomed at $52.5 million in Q1 2023.
• The 5-year median for Liabilities and Shareholders Equity is $421.1 million (2024), against an average of $370.9 million.
• The widest annual swing landed in 2022, when Liabilities and Shareholders Equity slumped 49.17%; it then surged 829.6% in 2024.
• A 5-year view of Liabilities and Shareholders Equity shows it stood at $71.1 million in 2022, then soared by 380.52% to $341.9 million in 2023, then soared by 77.99% to $608.5 million in 2024, then climbed by 27.82% to $777.8 million in 2025, then decreased by 1.78% to $764.0 million in 2026.
• The last three Liabilities and Shareholders Equity figures came in at $764.0 million (Q1 2026), $777.8 million (Q4 2025), and $504.6 million (Q3 2025), per Business Quant data.

Peer Comparison